ClinTec International appoints Alastair MacDonald as global head of Clinical Operations
ClinTec International has appointed Alastair MacDonald global head of Clinical Operations, as the organization continues to deliver on its ambitious global market-leading clinical research capabilities.
Alastair joins from AstraZeneca with almost 25 years’ experience in clinical development, most recently, as Global Medical Evidence and Observational Research Director at AstraZeneca. As a Global Delivery Director within AstraZeneca, Alastair made key contributions to the development pipeline and commercialization, with a focus on oncology, and within other key strategic AstraZeneca areas including Cardiovascular, Metabolic and Respiratory Medicine. His significant oncology background includes recent contributions to the development and subsequent commercialization of a number of key treatments across a broad range of cancer diseases.
Alastair was a board director of the Institute of Clinical Research (ICR), a premier organization responsible for education, training and career development of clinical research professionals in the U.K. In 2013 Alastair was awarded an Honorary Fellowship of the ICR. Alastair’s prior career includes the role of Regional Manager for SmithKline Beecham Pharmaceuticals (GlaxoSmithKline) ensuring clinical delivery for the U.K. local operating office and at Leo Pharmaceuticals, a Danish-based pharmaceutical company, where he specialized in the development of treatments for Dermatology and Pancreatic cancer.
Chief Operating Officer and Senior Executive Vice President of ClinTec International Robert Reekie commented, “As our company enters its 20th year of significant organic growth, we are delighted to have attracted Alastair to ClinTec International and look forward to bringing his industry leading operational talent and high calibre to bear in providing complementary leadership to our award winning clinical research project teams. In conjunction with our e-clinical technology platforms, this appointment further enhances our capability to meet and exceed the needs of our clients.”